Table 2.
Comparison of baseline characteristics between patients with progressive (≤ −1 ml/min per 1.73 m2 per year) and nonprogressive (> −1 ml/min per 1.73 m2 per year) eGFR slope (ml/min per 1.73 m2 per year)
| Characteristics | Progressive (n = 64) | Nonprogressive (n = 81) | P |
|---|---|---|---|
| eGFR slope (ml/min per 1.73 m2 per year) | −3.35 ± 2.31 | 1.64 ± 2.12 | <0.001 |
| Age (years) | 69.6 ± 12.5 | 67.7 ± 11.8 | 0.353 |
| Male gender (%) | 57.8 | 76.5 | 0.016 |
| Smoking history (%) | 63.5 | 50.6 | 0.122 |
| Diabetes mellitus (%) | 62.5 | 39.5 | 0.006 |
| Hypertension (%) | 90.6 | 79.0 | 0.057 |
| Coronary artery disease (%) | 14.1 | 22.2 | 0.210 |
| Cerebrovascular disease (%) | 23.4 | 16.0 | 0.263 |
| Stage of CKD | |||
| stage 3 (%) | 32.8 | 67.9 | <0.001 |
| stage 4 (%) | 35.9 | 22.2 | |
| stage 5 (%) | 31.3 | 9.9 | |
| Systolic BP (mmHg) | 147.4 ± 21.8 | 138.5 ± 20.1 | 0.012 |
| Diastolic BP (mmHg) | 79.5 ± 13.0 | 78.4 ± 10.3 | 0.581 |
| Pulse pressure (mmHg) | 67.9 ± 14.5 | 61.1 ± 18.2 | 0.016 |
| Heart rate (beats/min) | 77.6 ± 14.4 | 71.2 ± 12.6 | 0.005 |
| Body mass index (kg/m2) | 26.0 ± 5.6 | 25.9 ± 4.0 | 0.941 |
| Laboratory parameters | |||
| albumin (g/dl) | 3.96 ± 0.35 | 4.01 ± 0.33 | 0.362 |
| fasting glucose (mg/dl) | 131.1 ± 55.5 | 113.8 ± 34.8 | 0.032 |
| triglyceride (mg/dl) | 186.1 ± 120.2 | 150.6 ± 74.9 | 0.041 |
| total cholesterol (mg/dl) | 196.9 ± 46.6 | 195.6 ± 42.7 | 0.992 |
| HDL-cholesterol (mg/dl) | 44.9 ± 15.9 | 46.3 ± 11.3 | 0.543 |
| LDL-cholesterol (mg/dl) | 106.0 ± 32.9 | 117.1 ± 33.2 | 0.049 |
| hematocrit (%) | 33.5 ± 5.9 | 39.0 ± 6.1 | 0.001 |
| baseline eGFR (ml/min per 1.73 m2) | 23.1 ± 13.2 | 35.3 ± 13.5 | <0.001 |
| Calcium (mg/dl) | 9.5 ± 0.8 | 9.7 ± 0.6 | 0.061 |
| Phosphate (mg/dl) | 4.1 ± 1.0 | 3.6 ± 0.6 | <0.001 |
| Uric acid (mg/dl) | 8.4 ± 2.6 | 8.2 ± 2.1 | 0.669 |
| PTH (pg/ml) | 94.2 ± 144.0 | 42.7 ± 33.0 | 0.007 |
| Albuminuria (%) | 87.1 | 62.5 | 0.001 |
| baPWVa (cm/s) | 2285.4 ± 964.9 | 1871.2 ± 844.9 | 0.007 |
| Medications | |||
| aspirin use (%) | 31.7 | 26.3 | 0.471 |
| ACEI and/or ARB use (%) | 69.8 | 85.2 | 0.026 |
| β-blocker use (%) | 27.9 | 22.4 | 0.512 |
| calcium channel blocker use (%) | 62.5 | 53.1 | 0.255 |
| diuretic use (%) | 40.6 | 39.5 | 0.891 |
| statin use (%) | 23.8 | 30.0 | 0.409 |
| ESA use (%) | 10.9 | 4.9 | 0.215 |
a
Data were adjusted for mean arterial pressure.